Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China.

Front Oncol · 2022 · PMC9065445 · PMID 35515123

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the CheckMate 649 trial, the Chinese population showed a trend of greater benefit as compared with the global population, for example, 39% vs. 20% reduction in the risk of death and 43% vs. 23% reduction in the risk of disease progression or death.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.